Seventy-nine patients, or 45% of all re-classified patients, were moved from ELN-2017 favorable (n = 11) or intermediate (n = 68) to ELN-2022 adverse risk based on the inclusion of additional myelodysplasia-related (MR) mutations (BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) as poor-risk markers. This evidence concerns the gene STAG2 and Myelodysplasia.